01200-X/asset/f2ef2727-f32c-4146-a724-f0b9312e4d9f/main.assets/gr1_lrg.jpg)
surmount-1 tirzepatide non-diabetic obesity trial once weekly for the treatment of in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 Tirzepatide after intensive lifestyle intervention
Description
Food still tastes fine
For some, that is 10mg
00656-2/asset/38c98550-9ec2-44e8-ba6a-dbb815075666/main.assets/gr1_lrg.jpg)
In fact, clinical trial data shows improvements in psychological wellbeing in people taking tirzepatide
Further studies are required to clarify the complex interactions between GLP-1 RAs and various neuropsychiatric processes
A clinical trial conducted in May 2025 observed patients taking either drug for 72 weeks, looking closely at their percent change in weight
Its side effects are very similar overall but may feel milder for some people early in treatment
